Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy

[1]  M. Dieci,et al.  Phase III randomized study of adjuvant treatment with the ANTI-PD-L1 antibody avelumab for high-risk triple negative breast cancer patients: The A-BRAVE trial. , 2020 .

[2]  Amy M. Sitapati,et al.  Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

[3]  C. Perou,et al.  Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  S. Michiels,et al.  Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  H. Horlings,et al.  Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial , 2019, Nature Medicine.

[6]  S. Noguchi,et al.  PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive breast cancer , 2018, Breast Cancer Research and Treatment.

[7]  M. Ceppi,et al.  Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  D. Dabbs,et al.  Low Estrogen Receptor (ER)–Positive Breast Cancer and Neoadjuvant Systemic Chemotherapy: Is Response Similar to Typical ER-Positive or ER-Negative Disease? , 2018, American journal of clinical pathology.

[9]  L. Pusztai,et al.  Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  C. Perou,et al.  Defining breast cancer intrinsic subtypes by quantitative receptor expression. , 2015, The oncologist.

[11]  A. Luini,et al.  Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression. , 2014, Clinical breast cancer.

[12]  G. Hortobagyi,et al.  Which threshold for ER positivity? a retrospective study based on 9639 patients. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  N. Dendukuri,et al.  A Majority of Low (1-10%) ER Positive Breast Cancers Behave Like Hormone Receptor Negative Tumors , 2014, Journal of Cancer.

[14]  G. Hortobagyi,et al.  Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers , 2012, Cancer.

[15]  Yuan Qi,et al.  Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Craig D. Shriver,et al.  Effect of ASCO/CAP Guidelines for Determining ER Status on Molecular Subtype , 2012, Annals of Surgical Oncology.

[17]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.

[18]  P. Neven,et al.  Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  G. Hortobagyi,et al.  Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  C K Osborne,et al.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.